Company news

Cytokinetics, Incorporated news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Cytokinetics Announces Upcoming Presentations at the HCMS Scientific Sessions and the HFSA Annual Scientific Meeting

September 18, 2024

Cytokinetics Announces Data From Phase 1 Study of CK-4021586

September 8, 2024

Cytokinetics Announces Two Presentations at the 2024 American College of Clinical Pharmacology Annual Meeting

September 4, 2024

Cytokinetics Presents New Data Related to the Safety and Long-Term Use of Aficamten at the European Society of Cardiology Congress 2024

August 31, 2024

Cytokinetics Presents Additional Data From SEQUOIA-HCM at the European Society of Cardiology Congress 2024

August 31, 2024

Cytokinetics Reports Second Quarter 2024 Financial Results

August 7, 2024

Cytokinetics Announces Call for Proposals for Corporate Giving Program

July 29, 2024

Cytokinetics to Announce Second Quarter Results on August 8, 2024

July 24, 2024

Cytokinetics Announces Seven Upcoming Presentations at the European Society of Cardiology Congress 2024

July 15, 2024

Cytokinetics Announces Initiation of Phase 1 Study of Aficamten in Healthy Japanese Participants

June 16, 2024

Cytokinetics to Participate in June Investor Conferences

May 28, 2024

Cytokinetics Announces Closing of Public Offering of Common Stock

May 27, 2024

Cytokinetics Announces Proposed Public Offering of Common Stock

May 21, 2024

Cytokinetics Announces Pricing of Public Offering of Common Stock

May 21, 2024

Cytokinetics and Royalty Pharma Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline

May 21, 2024

Cytokinetics Hosts Muscle Biology-Focused Research Symposium: Contemporary Landscapes in Muscle Biology

May 16, 2024

Cytokinetics Announces Five Presentations Related to Aficamten at the European Society of Cardiology Congress 2024

May 14, 2024

Cytokinetics Announces Primary Results From SEQUOIA-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology Heart Failure 2024 Congress and Published in the New England Journal of Medicine

May 12, 2024

Cytokinetics Announces Additional Results From SEQUOIA-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology Heart Failure 2024 Congress

May 12, 2024

Cytokinetics Reports First Quarter 2024 Financial Results

May 7, 2024

Cytokinetics Announces Topline Data From Phase 1 Clinical Study of CK-4021586

May 7, 2024

Cytokinetics Announces Start of CEDAR-HCM, a Clinical Trial of Aficamten in a Pediatric Population With Symptomatic Obstructive Hypertrophic Cardiomyopathy

May 7, 2024

Cytokinetics to Host Investor Event and Conference Call to Discuss the Primary Results From SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 Congress

April 28, 2024

Cytokinetics to Announce First Quarter Results on May 8, 2024

April 23, 2024

Cytokinetics Announces Three Late Breaking Clinical Trial Presentations Relating to SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 Congress

April 9, 2024

Cytokinetics Presents Additional 48-Week Data From FOREST-HCM, the Open Label Extension Clinical Study of Aficamten, at The American College of Cardiology 73ʳᵈ Annual Scientific Session

April 4, 2024

Cytokinetics to Participate in the 23rd Annual Needham Virtual Healthcare Conference

March 31, 2024

Cytokinetics Announces Four Upcoming Presentations at the American College of Cardiology 73rd Annual Scientific Session

March 24, 2024

Cytokinetics Joins Global Initiative to Recognize International Rare Disease Day

February 28, 2024

Cytokinetics, The Mended Hearts, Inc. and WomenHeart Announce Launch of New Initiative to Increase Engagement in Cardiovascular Clinical Trials

February 27, 2024

Cytokinetics Reports Fourth Quarter 2023 Financial Results

February 26, 2024

Cytokinetics to Announce Fourth Quarter Results on February 27, 2024

February 12, 2024

Cytokinetics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

February 5, 2024

Cytokinetics Announces Recipients of Its Sixth Annual Communications Grant Program

January 28, 2024

Cytokinetics Presents New Data at CMR 2024 From FOREST-HCM, the Open Label Extension Clinical Trial of Aficamten

January 24, 2024

Cytokinetics Announces New Data From FOREST-HCM to be Presented at CMR 2024

January 17, 2024

Cytokinetics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

January 1, 2024

Cytokinetics Announces Positive Results From SEQUOIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy

December 26, 2023

Cytokinetics to Host Investor Call on December 27 to Discuss the Topline Results from SEQUOIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Obstructive Hypertrophic Cardiomyopathy

December 25, 2023

Cytokinetics Presents Results From COURAGE-ALS at the 34th International Symposium on ALS/MND

December 6, 2023

Cytokinetics Announces Five Presentations at the 34th International Symposium on ALS/MND

November 28, 2023

Cytokinetics Reports Third Quarter 2023 Financial Results

November 1, 2023

Cytokinetics to Participate in Upcoming Investor Conferences

October 31, 2023

Cytokinetics to Announce Third Quarter Results on November 2, 2023

October 22, 2023

Cytokinetics Provides Update on Cardiac Myosin Inhibitor Programs and Plans to Build a Specialty Cardiology Franchise at Virtual Investor & Analyst Day

October 18, 2023

Cytokinetics Presents Baseline Characteristics From SEQUOIA-HCM at the HCM Society Scientific Sessions

October 5, 2023

Cytokinetics to Host Virtual Investor & Analyst Day on October 19, 2023

October 4, 2023

Cytokinetics Announces Upcoming Presentations at the 2023 HCMS Scientific Sessions and the HFSA Annual Scientific Meeting

October 1, 2023

Cytokinetics Announces Call for Proposals for Its Sixth Annual Communications Grant Program

September 27, 2023

Cytokinetics Announces Start of ACACIA-HCM, a Pivotal Phase 3 Clinical Trial of Aficamten in Patients With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy

September 5, 2023

← Newer news releases · Older news releases →

Calls

The 5 newest of 23 calls. Every call is listed under its year.

Decks

The 5 newest of 44 decks. Every deck is listed under its year.